Mayo Foundation for Medical Education and Research

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Ic-medtech Corporation

Nicholas F LaRusso

Tetyana V Masyuk

Melissa Muff-Luett

Sergio A Gradilone

Thomas M Miller

Melissa A Muff

An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and &#x3b2;-catenin phosphorylation and/or acetylation while reducing bile duct &#x3b2;-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.

Treatment of polycystic diseases with an HDAC6 inhibitor

This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.

Treating liver diseases

Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NF&#x3ba;B-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K. Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.

Vitamins C and K for treating polycystic diseases

A method of inhibiting proliferation of bile duct epithelium, said method comprising the step of contacting said epithelium with an effective amount of somatostatin or a somatostatin agonist.

Growing community of inventors

Rochester, MN, United States of America

Nicholas F LaRusso